Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

VISTA UPDATE: INVO Bioscience (NASDAQ: INVO) Successfully Opens Its 2nd Advanced & Affordable Fertility Care INVO Center In The U.S.

By John F. Heerdink, Jr.
“The global fertility market size is predicted to hit around US$ 47.9 billion by 2030 with a CAGR of 4.7%”, according to new report study by Precedence Research. According to the data published by the National Center for Biotechnology Information (NCBI), “over 15% of couples are affected by fertility problems across the globe.” Depending on what statistics that you review today, Industry forecasts suggest that no more than 10% of the estimated 150 million infertile couples worldwide are currently being treated. INVO Bioscience’s (NASDAQ: INVO) mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity.

Today, September 7th, INVO Bioscience, Inc. (NASDAQ: INVO, $3.77/share), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area.

This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. INVO Bioscience’s INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). INVO Bioscience’s mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. Bloom Fertility, an INVO Center, is located at 6 Concourse Parkway, Suite 250, Atlanta GA 30328, PH# 678-597-9933.

Bloom Fertility, an INVO Center, is a partnership between INVO Bioscience and experienced reproductive specialist Dr. Sue Ellen Carpenter, MD. Dr. Carpenter is noted for excellence in her field and named a “Top Doctor, Atlanta 2019 and 2020.” She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society, and frequently delivers lectures across the country, having published more than a dozen papers on reproduction and fertility. INVO Bioscience has provided funding and operating costs and owns 40% of the Atlanta Joint Venture. The Atlanta-based INVO Center becomes the second INVO Center to open and will begin seeing patients immediately and perform initial INVOcell treatment cycles in the month of October 2021. 

Dr. Sue Ellen Carpenter, MD.,  Board Certified in Obstetrics and Gynecology

“This is an exciting time for patients in Atlanta that suffer from infertility. Bloom Fertility, an INVO Center, will offer the INVOcell solution for the many patients that remain underserved, and do so with a connected, intimate experience. I look forward to leveraging this technology through our new center, to bring the joy of parenthood to so many that have been dissuaded by the lack of affordable care or wary of traditional laboratory methods,” stated Dr. Sue Ellen Carpenter, MD.

Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO)

“We are thrilled today to officially open our Atlanta-based INVO Center. Bloom Fertility, an INVO Center, will look to advance our core mission of improving access to advanced fertility services for the many patients in Atlanta and the surrounding region. We have seen early success from our recently opened Birmingham-based INVO Center, with patient appointments and expected treatment cycles ahead of original expectations. We are excited to now open Atlanta and lead the democratization of advanced fertility treatment, which can be made possible by the revolutionary INVOcell solution,” Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO).


On Friday, September 3rd, INVO Bioscience, Inc. (NASDAQ: INVO, $3.77), announced that Dr. Inger Britt Carlsson, Vice President of Global Medical Affairs, will be presenting at the Association for Fertility and Reproductive Health (AFRH) virtual conference this year on September 23rd and 24th on the topic of INVOcell® as an efficient, patient-centric and affordable fertility solution for the continent of Africa. The INVOcell procedure is the first in-vivo culture (IVC) system in the world used for the incubation of eggs and sperm during fertilization and early embryo development within the body, as an alternative to conventional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Through its in vivo approach, INVOcell offers patients a more natural and intimate experience.



“Across the African continent, infertility is on the rise, with an average infertility rate of 10.1% and as high as 32% in some countries. Infertility comes with devastating social, cultural, emotional and economic consequences for young couples in Africa. Unfortunately, accessing basic assisted reproductive technology treatments can be challenging or impossible for couples who have issues conceiving. The INVOcell solution is a low-cost and effective fertility treatment option that can be the answer to this burgeoning dilemma,” stated Dr. Inger Britt Carlsson, Vice President of Global Medical Affairs of INVO Bioscience (INVO).

Prior to the start of the pandemic, INVO Bioscience entered into a distribution agreement in Nigeria, the most populous (~212 million) country in Africa, with G-Systems. They have recently completed the registration process in Nigeria as well as hosted training events with our distributor. They believe the African continent represents an attractive opportunity for INVOcell and look forward to accelerating our efforts to democratize fertility across the African continent.


Steve Shum, CEO Of INVO Bioscience (NASDAQ: INVO)

“Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, Alabama. We feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years:

  1. Our Team – An experienced internal operating team with key positions filled, a strong and diverse board of directors, a scientific advisory board composed of well-known and respected fertility industry experts, and key outside KOL’s/consultants.

  2. Our Partners – A growing list of quality distributors around the world, experienced and motivated JV Partners, and a committed shareholder base.

  3. Our Technology – We have gained valuable real market usage data (and hence further validation) along with a clear understanding of how our technology “fits” in the industry and the key challenges it helps solve.

Fertilization and early embryo development happens within the INVOcell device

“We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need. The new Birmingham practice, our very first INVO Center, is a major milestone and one of the most significant in the Company’s history to date. The center is already off to an encouraging start as we have surpassed our internal expectations for patient appointments and expected treatment cycles planned for the first month. The vision to drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry is coming to reality with this first INVO Center, thanks to the expertise and commitment of our internal team and partners. Our goal to democratize fertility treatment by bringing care to the vast underserved patient population around the world experiencing infertility challenges is advancing. We believe a key to this effort will also involve leveraging the OB/GYN community. In July, we appointed Dr. Barbara Levy as our SVP, global clinical integration. Dr. Levy is considered one of the most influential fertility and reproductive health clinical executives in the world and brings a life-long passion to improving women’s health recognizing that a critical component to that is treatment for infertility. I am excited to have Dr. Levy help lead this OB/GYN strategy moving forward,” stated Steve Shum, CEO Of INVO Bioscience (NASDAQ: INVO). 


Mike Campbell, COO of INVO Bioscience (NASDAQ: INVO)

“With the blueprints now firmly in place for our INVO Center model, we are rapidly moving towards the opening of centers in Atlanta, Monterrey, Mexico and the San Francisco Bay area. We expect that Atlanta and Monterrey centers will both be opened before the end of the year, as site selections are complete, equipment has been ordered, staffing is ramping up, and marketing plans are in place. A San Francisco Bay area center should be opened shortly thereafter and our ongoing discussions with additional partners remain active. This is an exciting time for INVO as we have diversified our business model beyond device sales exclusively through our distributors, to a model where we will capture a share of the larger revenue generated by the entire INVO patient solution,” stated Mike Campbell, COO of INVO Bioscience (NASDAQ: INVO).


David Sable (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company

On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing.

*The current issued and outstanding shares for INVO, according to Yahoo Finance, is only 10.47 million shares, which squarely positions this stock in ‘tightly held’ or low float category. The 52- week trading range for INVO is $2.90 – $12.30. 


Barbara Ryan is an INVO Bioscience Board Member

INVO has also transformed their board of directors adding a couple of powerful global thought leaders including Barbara Ryan, a Corporate (Public) Board Member with expertise in Healthcare and Life Science Capital Markets – Audit -Strategic Counselor to CEO/C-Suite within Biopharma & Med-Tech with 31 Years of experience working on Wall Street as Pharmaceutical Analyst and Managing Director and a frequent guest expert on CNBC. INVO also recently added Rebecca Messina. Messina has broad international experience in leading marketing for elite brands and businesses including Uber Technologies (UBER), Beam Suntory and The Coca-Cola Company (KO). She is currently a Senior Advisor at McKinsey & Company focused on advising internal teams and firm clients in the areas of marketing as a growth lever, including data driven marketing, brand building, and strategically shaping and transforming marketing agendas.

Rebecca Messina is an INVO Bioscience Board Member


“Democratizing Infertility – A Severely Underserved Global Market”

On April 13,  INVO’s CEO Steve Shum delivered his presentation is titled “Democratizing Infertility – A Severely Underserved Global Market.” You may view the video of the event now at this link: https://youtu.be/w4yQIc7eO5k.


In yet another progressive move, INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Culture System (IVC), INVOcell® announced on June 14th that they had the appointed Barbara Levy, M.D., FACOG, FACS as the Company’s Senior VP, Global Clinical Integration. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee. She joins INVO Bioscience to help further develop and accelerate the Company’s global OB/GYN channel strategy. Dr. Levy has been a vocal advocate for women’s health and health equity with appearances on The Oprah Winfrey Show and multiple other media outlets. Her research interests span from outcomes research in minimally invasive gynecologic surgery to optimizing care for women with chronic pelvic pain. Her clinical work focused on evidence-based, equitable, comprehensive care for women throughout their life course. She has published and co-authored over 85 studies.

Barbara Levy, M.D., FACOG, FACS as the Company’s Senior VP, Global Clinical Integration at INVO Bioscience

“Women’s healthcare has been a life-long passion for me and a critical component of improving women’s health and wellbeing is treatment for infertility. There is a large unmet need for efficient and scalable advanced treatment options, that are also accessible and affordable, to help bring equity to the large underserved patient population suffering from infertility. I believe IVC and the INVOcell technology provides a unique market solution and am excited to be joining the INVO Bioscience team to focus on quality and outcomes for patients and to support fertility practice healthcare professionals,” stated Barbara Levy, M.D., FACOG, FACS as the Company’s Senior VP, Global Clinical Integration at INVO Bioscience.

Dr. Levy is an advocate for advancing the quality of women’s health. Dr. Levy was in private practice in comprehensive holistic women’s health for over 30 years and served as a Medical Director for Women’s and Children’s Services for the Franciscan Health System in Washington State. She has served as a reviewer and editor for several medical journals, including Obstetrics & Gynecology, American Journal of Obstetrics and Gynecology, JAMA, JMIG, Fertility and Sterility.

In 2012 Dr. Levy joined the American College of Obstetricians and Gynecologists (ACOG) as Vice President for Health Policy, directing the expansion of the Advocacy Division to support implementation of best practices in women’s health. She built a team dedicated to improvement in health equity and outcomes in maternity care, primary women’s healthcare, and surgical interventions.

Dr. Levy graduated magna cum laude from Princeton University. She obtained her medical degree from the University of California, San Diego, followed by an internship and residency at the Oregon Health Sciences University.


Over the past 40+ years, since the first IVF baby was born, the fertility market has grown into a $20+ billion global industry. Here in the U.S., according to the most recent 2019 CDC data, approximately 330,000 IVF cycles were performed across 448 clinics, which implies a roughly $5 billion domestic marketplace. However, this represents only a small portion of the actual market as approximately 90% of infertile couples go untreated each year. There are some real challenges with bridging the gap of treating the volume of patients that need care. Patient affordability and lack of insurance coverage is often the most discussed dynamic, but that is only one part of the challenge.

We believe that there is an equal or even greater challenge related to capacity limitations in the industry given the relatively small number of IVF clinics and limited human resources available which are typically only available in major metropolitan areas. We believe that INVO Bioscience’s INVOcell, which does not require the process of building out and maintaining expensive lab build outs, can bring much needed capacity additions and access to the market beyond the major metropolitan areas at a more affordable price and into the rural areas as well located throughout the world.



Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us